These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154 [TBL] [Abstract][Full Text] [Related]
5. Quality of bevacizumab (Avastin®) repacked in single-use glass vials for intravitreal administration. Sugimoto MAA; Toledo VPCP; Cunha MRR; Carregal VM; Jorge R; Leão P; Fialho SL; Silva-Cunha A Arq Bras Oftalmol; 2017; 80(2):108-113. PubMed ID: 28591284 [TBL] [Abstract][Full Text] [Related]
6. Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs. Takahashi H; Nomura Y; Nishida J; Fujino Y; Yanagi Y; Kawashima H Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):462-6. PubMed ID: 26868748 [TBL] [Abstract][Full Text] [Related]
7. Biological drug therapy for ocular angiogenesis: Anti-VEGF agents and novel strategies based on nanotechnology. Formica ML; Awde Alfonso HG; Palma SD Pharmacol Res Perspect; 2021 Apr; 9(2):e00723. PubMed ID: 33694304 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration. Luaces-Rodríguez A; Mondelo-García C; Zarra-Ferro I; González-Barcia M; Aguiar P; Fernández-Ferreiro A; Otero-Espinar FJ Int J Pharm; 2020 Jan; 573():118767. PubMed ID: 31669558 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the sterility, stability, and efficacy of bevacizumab stored in multiple-dose vials for 6 months. Chen YH; Wu PC; Shiea J; Lo LH; Wu YC; Kuo HK J Ocul Pharmacol Ther; 2009 Feb; 25(1):65-9. PubMed ID: 19232008 [TBL] [Abstract][Full Text] [Related]
10. Chitosan-Polycaprolactone Core-Shell Microparticles for Sustained Delivery of Bevacizumab. Jiang P; Jacobs KM; Ohr MP; Swindle-Reilly KE Mol Pharm; 2020 Jul; 17(7):2570-2584. PubMed ID: 32484677 [TBL] [Abstract][Full Text] [Related]
11. EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Lee JH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS Retina; 2019 Oct; 39(10):1953-1958. PubMed ID: 30161096 [TBL] [Abstract][Full Text] [Related]
12. Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab. Wang D; Choi KS; Lee SJ Korean J Ophthalmol; 2014 Feb; 28(1):32-8. PubMed ID: 24505199 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. Jeganathan VS; Verma N Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163 [TBL] [Abstract][Full Text] [Related]
14. INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Storey PP; Ho V; Yeh S; Reddy S; Fang-Yen NH; Pequignot E; Leiby BE; Fineman M; Garg S; Hubbard GB; Hsu J Retina; 2015 Oct; 35(10):1992-2000. PubMed ID: 26035396 [TBL] [Abstract][Full Text] [Related]
15. Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration. Paul M; Vieillard V; Roumi E; Cauvin A; Despiau MC; Laurent M; Astier A Ann Pharm Fr; 2012 May; 70(3):139-54. PubMed ID: 22655582 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A Retina; 2007; 27(4):432-8. PubMed ID: 17420694 [TBL] [Abstract][Full Text] [Related]
18. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA; Retina; 2008; 28(10):1387-94. PubMed ID: 18827735 [TBL] [Abstract][Full Text] [Related]
19. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630 [TBL] [Abstract][Full Text] [Related]
20. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]